Published by Josh White on 26th January 2021
(Sharecast News) - Clinical-stage biopharmaceuticals company Faron Pharmaceuticals announced on Tuesday that the United States Food and Drug Administration (FDA) has approved the phase 2 and 3 'HIBISCUS' trial assessing its intravenous IFN beta-1a 'Traumakine' for the treatment of hospitalised patients with Covid-19.